Despite completion of more than 9 million procedures each year in France, the best antiseptic solution to be used for preparing the skin to reduce risk of surgical site infection (SSI) remains unknown. 2% Chlorhexidine gluconate (CHG)-alcohol is superior to Povidone Iodine (PVI)-alcohol for short term vascular catheter care (Mimoz O, Lancet 2015; Pages J, Intensive Care Med 2016), but studies comparing both antiseptic solutions for clean-contaminated surgical procedures led to conflicting results. The present study will be the first large scale multicenter randomized controlled trial adequately powered to compare efficacy and safety of CHG-alcohol over PVI-alcohol in reducing SSI after clean surgery. A clean surgery was chosen because pathogens involved in SSI mostly originate from skin. Therefore, optimisation of skin disinfection before surgery has the potential to reduce the incidence of SSI. Cardiac surgery was chosen because SSI may be severe, diagnosis of SSI is easy to monitor and to define and infections arise earlier than other frequent clean surgeries using implants such as orthopaedic or vascular surgery. The incidence of reoperation for any purpose will be used as the main objective because there are easy to track and define and are less susceptible to interpretation in an open trial than superficial SSI. According to CDC criteria, patients will be monitored up to Day 90 because mediastinitis after cardiac surgery may occur after the usual 30-day SSI surveillance period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
3,316
2% Chlorhexidine-70% isopropanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
5%Povidone Iodine- 69%Ethanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
University Hospital of Clermont-Ferrand
Clermont-Ferrand, France
University Hospital of Nantes
Nantes, France
La Pitié Salpétrière Hospital
Paris, France
Institut Mutualiste Montsouris
Paris, France
University Hospital of Poitiers
Poitiers, France
University Hospital of Rennes
Rennes, France
CHRU de Strasbourg
Strasbourg, France
CHU de Toulouse
Toulouse, France
Incidence of any re-sternotomy occurring between Day 0 and Day 90 after surgery
Time frame: 90 days
Incidence of any reoperation on saphen venous/radial artery site occurring between Day 0 and Day 30 after surgery.
Time frame: 30 days
Incidence of mediastinitis according to CDC criteria occurring by Day 90 after surgery and pathogens involved
Time frame: 90 days
Incidence of deep incisional SSIs at saphen venous/radial artery site according to CDC criteria occurring by Day 30 after surgery and pathogens involved
Time frame: 30 days
Incidence of superficial incisional SSIs at sternal or saphen venous/radial artery sites according to CDC criteria occurring by Day 30 after surgery and pathogens involved
Time frame: 30 days
Incidence of SWI requiring reoperation, occurring by Day 90
Time frame: 90 days
Incidence of SSIs at saphen venous/radial artery site requiring reoperation, occurring by Day 30
Time frame: 30 days
Incidence of unexpected need for re-admission to the ICU or re-hospitalisation
Time frame: 90 days
Number of days in ICU
Time frame: 90 days
Number of days under mechanical ventilation
Time frame: 90 days
Number of days in Hospital
Time frame: 90 days
Number of days in rehabilitation unit
Time frame: 90 days
Mortality at Day 90 of surgery
Time frame: 90 days
Incidence of local and systemic side effects possibly linked to antiseptic use
Time frame: 90 days
Economic analysis including cost-effectiveness of surgical skin antisepsis
Time frame: 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.